Compare Petróleo Brasileiro SA (PBR) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Regeneron Pharmaceuticals Inc — how do they compare? Petróleo Brasileiro SA trades at $25.3 (market cap $151.94B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Petróleo Brasileiro SA is the larger of the two by market cap, and Petróleo Brasileiro SA pays the higher dividend (6.79%). Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PBR | REGN | |
|---|---|---|
Market Cap | $151.94B | $76.14B |
Volume | 30,240,092 | 500,239 |
Sector | Energy | Health |
52-Week High | $25.30 | $852.03 |
52-Week Low | $11.54 | $557.73 |
Typical Hold Time | 25 Days | 107 Days |
Enterprise Value | $212.36B | $70.85B |
Dividend Yield | 6.79% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $24.69, up 2.92% with strong bullish momentum. The stock shows robust fundamentals with a low P/E of 6.24, ROE of 30.77%, and consistent earnings beats. Recent developments include new oil discoveries and LNG supply agreements, while technical indicators show overbought conditions with RSI above 80. Analyst consensus leans bullish with 50% buy ratings.
PBR offers compelling value with strong profitability and growth prospects, though elevated RSI suggests near-term consolidation risk. The company's expansion projects and dividend policy support long-term upside, but investors should monitor oil price volatility and Brazilian political factors that could impact operations.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
